Rigidification Dramatically Improves Inhibitor Selectivity for RAF Kinases

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Oncology

Background:

• RAF kinases are crucial cancer drug targets.
• Current inhibitors often target the inactive RAF kinase state.
• Previous work showed inhibitor rigidification can improve RAF kinase selectivity.

Purpose of the Study:

• To investigate if rigidification of a different pyrazolopyrimidine scaffold can enhance RAF kinase selectivity.
• To characterize the binding mode of the optimized inhibitor.
• To evaluate the anti-cancer efficacy of the optimized inhibitor in cell lines.

Main Methods:

• Inhibitor design and synthesis involving ring closure for rigidification.
• Kinase selectivity screening against a panel of kinases.
• X-ray crystallography to determine inhibitor-bound kinase structure.
• Cell proliferation assays using cancer cell lines.

Main Results:

• A novel pyrazolopyrimidine-based inhibitor (2l) demonstrated dramatically improved selectivity for RAF kinases.
• Crystal structure revealed inhibitor 2l binds to an active-like BRAF conformation.
• Inhibitor 2l selectively inhibited proliferation of BRAF^V600E-mutant cancer cell lines.

Conclusions:

• Inhibitor rigidification is a potent strategy for achieving high selectivity against protein kinases.
• This approach may offer new therapeutic opportunities for cancer treatment.
• The optimized inhibitor 2l shows potential as a targeted cancer therapy.